<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01418053</url>
  </required_header>
  <id_info>
    <org_study_id>11-4627 CarO</org_study_id>
    <nct_id>NCT01418053</nct_id>
  </id_info>
  <brief_title>The Effect of Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome</brief_title>
  <acronym>CarO</acronym>
  <official_title>Randomised Controlled Study on the Effect of a Kneipp Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität Duisburg-Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a daily use of a Kneipp hot cataplasm with
      caraway oil is effective in the treatment of abdominal pain and complaints caused by
      Irritable bowel syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irritable Bowel Syndrome - Symptom Severity Score</measure>
    <time_frame>at T2 (Day 21)</time_frame>
    <description>IBS-SSS (Francis 1997)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of abdominal discomfort/Pain</measure>
    <time_frame>last week of treatment (days 14-21)</time_frame>
    <description>Diary, daily rating of pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of abdominal discomfort/Pain</measure>
    <time_frame>last week of treatment (days 14-21)</time_frame>
    <description>Daily rating of pain intensity on a 100mm Visual analogue scale, pain diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>T2 (Day 21)</time_frame>
    <description>measured with the EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - ibs specific</measure>
    <time_frame>T2 (day 21)</time_frame>
    <description>measured with the IBS-QOL (Patrick, 1998)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression and Anxiety</measure>
    <time_frame>T2 (day 21)</time_frame>
    <description>HADS questionnaire (Hermann, 1995)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global improvement</measure>
    <time_frame>At day 7, 14 and 21</time_frame>
    <description>Question on global improvement: How have your symptomes changed compared to the last week: from much worse to much better on a 7-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>h-BD2</measure>
    <time_frame>T2 (day 21)</time_frame>
    <description>h-BD2 laboratory findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate Relief Score</measure>
    <time_frame>at day 7, 14, 21</time_frame>
    <description>Adequate Relief Score (Mangel, 1998)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Hot Cataplasm with Caraway Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hot Cataplasm with Olive oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold cataplasm with Olive oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caraway oil</intervention_name>
    <description>essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm</description>
    <arm_group_label>Hot Cataplasm with Caraway Oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olive oil</intervention_name>
    <description>1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned</description>
    <arm_group_label>Hot Cataplasm with Olive oil</arm_group_label>
    <arm_group_label>Cold cataplasm with Olive oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Irritable Bowel Syndrome according to Rom-III

          -  Subtype Diarrhea or Alternating

          -  discomfort or pain &gt; 1 times a week

          -  discomfort or pain &gt; 4 on a Visual Analog Scale

        Exclusion Criteria:

          -  Inflammatory bowel diseases (test results necessary)

          -  Lactose, Fructose Malabsorption (test results necessary)

          -  Celiac Disease

          -  Pregnancy or Breastfeeding

          -  Colectomy or Hemicolectomy &gt;50cm

          -  Severe metabolic disorders, hormonal disorders, cardiac or respiratory failure, liver
             or renal diseases

          -  severe depression, psychotic or psychiatric disorders, substance abuse

          -  cancer within the last 5 years

          -  allergy to caraway

          -  acute inflammatory diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jost Langhorst, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Duisburg-Essen, Chair of Integrative Gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Naturheilkunde und Integrative Medizin</name>
      <address>
        <city>Essen</city>
        <zip>45276</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Lauche R, Janzen A, Lüdtke R, Cramer H, Dobos G, Langhorst J. Efficacy of Caraway Oil Poultices in Treating Irritable Bowel Syndrome--A Randomized Controlled Cross-Over Trial. Digestion. 2015;92(1):22-31. doi: 10.1159/000398790. Epub 2015 Jun 5.</citation>
    <PMID>26044145</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2011</study_first_submitted>
  <study_first_submitted_qc>August 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität Duisburg-Essen</investigator_affiliation>
    <investigator_full_name>Jost Langhorst</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

